Speaker Profile
Ph.D., Vice President, Research & Development, Castle Biosciences
Biography
Dr. Rebecca Critchley-Thorne joined Castle Biosciences in December 2021 as Vice President, RD, Spatialomics and GI, as part of the acquisition of Cernostics Inc., where she was Co-Founder and Chief Scientific Officer. She led the development of the Tissue Cypher computational pathology platform as well as the Tissue Cypher Barretts Esophagus test and its supporting clinical studies. She currently oversees RD for Castles commercially available tests and pipeline activities. She completed training as a postdoctoral fellow at Stanford University, where she focused on highly multiplexed analysis of biomarkers to understand mechanisms of immune dysfunction in various cancer types. She completed doctoral work in cancer immunotherapy at Imperial College and Cancer Research UK in London, UK, and earned a B. S. (Hons) degree in Pharmacology from the University of Sheffield, UK. Dr. Critchley-Thorne is the author of many medical and scientific publications, a principal investigator on NIH-funded research studies, and an inventor on several of Castle's patents.
Session Abstract – PMWC 2027 Silicon Valley
The PMWC 2026 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
